Get the Stockscreener App
9.23
0.65%
-0.06
After Hours:
9.23
89 Bio Inc stock is traded at $9.23, with a volume of 820.61K.
It is down -0.65% in the last 24 hours and up +28.37% over the past month.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
See More
Previous Close:
$9.29
Open:
$9.25
24h Volume:
820.61K
Relative Volume:
1.49
Market Cap:
$977.55M
Revenue:
-
Net Income/Loss:
$-174.61M
P/E Ratio:
-4.3744
EPS:
-2.11
Net Cash Flow:
$-165.54M
1W Performance:
+12.84%
1M Performance:
+28.37%
6M Performance:
+0.11%
1Y Performance:
+9.75%
1-Day Range:
$8.98
$9.49
1-Week Range:
$7.67
$9.52
52-Week Range:
$6.8802
$16.63
89 Bio Inc Stock (ETNB) Company Profile
Name
89 Bio Inc
Sector
Industry
Phone
(415) 432-9270
Address
142 SANSOME STREET, SAN FRANCISCO, CA
89 Bio Inc Stock (ETNB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-12-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-20-21 | Initiated | H.C. Wainwright | Buy |
| Oct-26-21 | Resumed | Cantor Fitzgerald | Overweight |
| Jul-29-21 | Resumed | BTIG Research | Buy |
| May-25-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-21-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-20 | Initiated | Raymond James | Strong Buy |
| Sep-25-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jul-23-20 | Initiated | BTIG Research | Buy |
| Jul-07-20 | Initiated | Chardan Capital Markets | Buy |
| Dec-09-19 | Initiated | BofA/Merrill | Neutral |
| Dec-09-19 | Initiated | Oppenheimer | Outperform |
| Dec-09-19 | Initiated | RBC Capital Mkts | Outperform |
| Dec-09-19 | Initiated | SVB Leerink | Outperform |
View All
89 Bio Inc Stock (ETNB) Latest News
89bio to Participate in the UBS Global Healthcare Conference - The Manila Times
89bio (NASDAQ:ETNB) Shares Gap DownShould You Sell? - MarketBeat
Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH - Yahoo Finance
89bio's chief technical operations officer sells $226,994 in stock - Investing.com India
89bio's chief technical operations officer sells $226,994 in stock By Investing.com - Investing.com Australia
89bio (NASDAQ:ETNB) Trading 7.3% HigherStill a Buy? - MarketBeat
89Bio: Surviving A Competitive SpaceFor Now (NASDAQ:ETNB) - Seeking Alpha
Global Severe Hypertriglyceridemia (SHTG) Treatment Market Set to Reach USD 2675.37 Million by 2033 - PharmiWeb.com
Canadian North Resources Inc. Reports Metal Extraction of 96-98% Nickel and Cobalt Using Low-carbon Footprint - EIN News
Canadian North Resources Inc. Reports Metal Extraction of 96-98% Nickel and Cobalt Using Low-carbon Footprint Bio-Leaching Technology for the Ferguson Lake Project - The Manila Times
Canadian North Resources Inc. Reports Metal Extraction of - GlobeNewswire
Oak Valley Bancorp reports Q3 EPS 89c vs. 89c last year - Yahoo Finance
Deckers Stock Rallies 89% in a Year: Lock in Gains or Stay Invested? - Yahoo Finance
89bio, Inc. (NASDAQ:ETNB) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Suvretta Capital Management's Strategic Reduction in 89bio Inc Holdings - Yahoo Finance
89bio, Inc. (NASDAQ:ETNB) Short Interest Update - MarketBeat
State Street Corp's Strategic Acquisition in 89bio Inc - Yahoo Finance
89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024 - The Manila Times
89bio Inc (ETNB) presents a great opportunity, but the stock is slightly overvalued - US Post News
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
PCR Technologies Market to Hit USD 21.89 Billion by 2030 with 7.7% CAGR | MarketsandMarkets™ - PR Newswire
Millennium Management LLC Sells 76,845 Shares of 89bio, Inc. (NASDAQ:ETNB) - MarketBeat
89bio (NASDAQ:ETNB) Trading Up 5.3%Here's Why - MarketBeat
89bio Inc [ETNB] Chief Executive Officer makes an insider purchase of 52,718 shares worth 0.58 million. - Knox Daily
Renaissance Technologies LLC Invests $2.24 Million in 89bio, Inc. (NASDAQ:ETNB) - MarketBeat
Bank of Montreal Can Has $4.64 Million Stake in Repligen Co. (NASDAQ:RGEN) - Defense World
89bio Inc (ETNB)’s stock price range in the last year - US Post News
89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference - ForexTV.com
The Potential Rise in the Price of 89bio Inc (ETNB) following insiders activity - Knox Daily
What is 89bio Inc (ETNB) Stock Return on Shareholders’ Capital? - SETE News
Metric Deep Dive: Understanding 89bio Inc (ETNB) Through its Ratios - The Dwinnex
Severe Hypertriglyceridemia Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Ionis Pharma, 89bio, Inc., Arrowhead Pharma, Hightide Therapeutics, AstraZeneca, Kowa - Barchart
Severe Hypertriglyceridemia Market Growth to Accelerate - openPR
89Bio's SWOT analysis: pegoza's potential in competitive MASH market - Investing.com
89Bio's SWOT analysis: pegoza's potential in competitive MASH market By Investing.com - Investing.com Australia
Health Check: How Prudently Does 89bio (NASDAQ:ETNB) Use Debt? - Simply Wall St
89bio Inc (ETNB) did well last session? - US Post News
In the Green: 89bio Inc (ETNB) Closes at 7.67, Up/Down -6.35 from Previous Day - The Dwinnex
89bio (NASDAQ:ETNB) Trading Down 2.9% - MarketBeat
89bio, Inc. (NASDAQ:ETNB) Receives $30.14 Average PT from Brokerages - MarketBeat
Adversity is less terrifying than hope: 89bio Inc (ETNB) - SETE News
Integral Health Asset Management LLC Buys 150,000 Shares of 89bio, Inc. (NASDAQ:ETNB) - MarketBeat
89bio's (ETNB) "Overweight" Rating Reiterated at Cantor Fitzgerald - MarketBeat
Balakrishna pays tribute to ANR on his 100th Birth Anniversary - TrackTollywood
2 Kite vets fly over to Kyverna Therapeutics—Chutes & Ladders - Fierce Biotech
Saba capital management sells shares in Eaton Vance trust worth over $484k - Investing.com
Brokerages Set East West Bancorp, Inc. (NASDAQ:EWBC) Price Target at $89.53 - Defense World
Ratio Examination: 89bio Inc (ETNB)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Teresa Perney brought in to lead 89bio’s regulatory strategy - The Pharma Letter
Bank of New York Mellon Corp Has $2.40 Million Stake in 89bio, Inc. (NASDAQ:ETNB) - Defense World
Peter Maag resigns as Kyverna CEO - BioCentury
89 Bio Inc Stock (ETNB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):